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MatrixCandida tropicalis has emerged as one of themost prevalent fungal pathogens, and its ability to form bioﬁlms has
been considered one of the most important virulence factors, since they represent high tolerance to antifungal
agents. However, the mechanisms of bioﬁlm resistance to antifungal agents remain poorly understood. Thus,
the main goal of this study was to infer about the ability of amphotericin B (AMB) to control and combat
C. tropicalis bioﬁlms. Additionally, it was also intended to determine the inﬂuence of matrix components in bio-
ﬁlm resistance. AMB was unable to totally prevent bioﬁlm formation and to eradicate C. tropicalis preformed
bioﬁlms.Moreover, AMB led to a signiﬁcant increase of the bioﬁlmproduction due to an augment of the total pro-
tein and carbohydrate contents of thematrix. The C. tropicalis bioﬁlmmatrix assumes an important role on its re-
sistance to AMB.351-253604424.© 2015 Elsevier Inc. All rights reserved.1. Introduction
Candidiasis is the most prevalent opportunistic fungal infection on
humans and, as such, a major public health problem (Silva et al.,
2012). In the recent decades, candidiasis have been associated to Candi-
da tropicalis, and it has been reported as an important causative agent of
the bloodstream and urinary tract infections in hospitalized patients,
causing high mortality and morbidity (Negri et al., 2010, 2012; Silva
et al., 2012).
During the last decades, the levels of candidiasis due to C. tropicalis
have been increasing, and it could be attributed to the greater use of an-
tifungal agents nowadays and over long periods of time, which enabled
an increase of resistance of C. tropicalis to certain antifungal agents, spe-
ciﬁcally to amphotericin B (AMB) (Muñoz et al., 2011; Negri et al.,
2012). In clinical practice, AMB, belonging to the polyene group, is 1 of
the antifungal agents most commonly used to treat candidiasis (Silva
et al., 2012; Williams et al., 2011).
Bioﬁlms have been considered the most prevalent growth form of
microorganisms and 1 of the virulence factors that mostly contribute
to the pathogenicity of Candida species (Negri et al., 2012; Silva et al.,
2011, 2012). Moreover, from the clinical perspective, the most impor-
tant feature of Candida bioﬁlms is its role in increasing tolerance to con-
ventional antifungal therapy (Silva et al., 2012).
However, despite that there is some knowledge about the effect of
AMB against C. tropicalis planktonic cells (Negri et al., 2010; Silva
et al., 2012), there is a lack of information concerning its role on C.
tropicalis bioﬁlms. Thus, the main aim of this work was to infer aboutthe AMB ability to control and combat C. tropicalis bioﬁlms and to deter-
mine the inﬂuence of matrix in the bioﬁlm resistance.
2. Materials and methods
2.1. Organisms and growth conditions
A total of 3 different C. tropicalis strains were used during this work:
1 oral strain (AG1), from the bioﬁlm group of the Centre of Biological
Engineering, originally isolated from Clinic Dentistry, Congregados,
Braga, Portugal; 1 urinary tract strain (519468), recovered frompatients
of the Hospital of S. Marcos, Braga, Portugal; and 1 vaginal strain (12),
obtained from the archive collection of the University of Maringá,
Brazil. The identiﬁcation of all isolateswas conﬁrmed using CHROMagar
Candidamedium (CHROMagar, Paris, France) and by polymerase chain
reaction (PCR)–based sequencing using speciﬁc primers (ITS1 and ITS4)
against the 5.8S subunit gene reference. Genomic deoxyribonucleic acid
(DNA) was extracted following previously described procedures
(Williams et al., 1995). The PCR products were sequenced using the
ABI-PRISM Big Dye terminator cycle sequencing kit (Perkin Elmer; Ap-
plied Biosystems, Warrington, UK). For all experiments, C. tropicalis
strains were subcultured on Sabouraud dextrose agar medium (SDA;
Merck, Darmstadt, Germany) for 48 h at 37 °C.
2.2. Minimum inhibitory concentrations determination
MICs of C. tropicalis strainswere determined for the antifungal agent
AMB (Pﬁzer, NY, USA), using the microdilution method, in accordance
with the guidelines of the Clinical and Laboratory Standards Institute
(CLSI) (Pfaller et al., 2008). The AMB concentrations tested were 0.5,
1, 1.5, 2, 2.5, 4, and 6 mg/L.
Table 1
C. tropicalisMICs obtained with AMB
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new well microplate, and serial dilutions were plated in SDA at 37 °C.
After 24 h of incubation, the total number of colony-forming units
(CFUs) was determined, and the results were presented as Log10 CFUs
per milliliter (Log10 CFUs/mL).
Assessments of the response proﬁles with different antifungal
agents were performed in triplicate and on 3 different occasions.
2.3. Bioﬁlm formation
An inoculum of each yeast strain, obtained from SDA plates, was re-
suspended in 30mL of Sabouraud dextrose brothmedium (SDB;Merck,
Darmstadt, Germany) and incubated for 16–18 h at 37 °C, under agita-
tion at 120 rpm. Then, cells were harvested by centrifugation at 5000g
for 10 min at 4 °C and washed twice with phosphate-buffered saline
(PBS), pH 7.0, 0.1 mol/L. The pellets were then resuspended in PBS.
Prior to being used in each experiment, the cellular density adjusted to
2 × 105 cells/mL, in Roswell Park Memorial Institute 1640 medium
(RPMI; Sigma, St. Louis, MO, USA) supplemented with 2% of glucose,
using a Neubauer counting chamber.
2.3.1. Inﬂuence of AMB in bioﬁlm formation
In order to study the effect AMB on C. tropicalis bioﬁlm formation, dif-
ferent concentrations of the agent (0.5, 1, and 2 mg/L) were prepared in
RPMI medium and added at the beginning of the bioﬁlm process forma-
tion. AMB solutions were prepared with twice the concentration tested
in RPMImedium, from stock solutions of 1000mg/L in dimethyl sulfoxide
(Sigma). Cells were prepared as described above, and each well of a
96-wellmicroplate (Orange Scientiﬁc, Braine-l’Alleud, Belgium)wasﬁlled
with 100 μL of the antifungal agent and100 μL of the standardized cell sus-
pension. Controlswere also performedwithCandida cellswithout antifun-
gal agents. Themicroplates were incubated for 48 h at 37 °C and 120 rpm.
The experiments were repeated in triplicate in 3 different occasions.
2.3.2. Inﬂuence of AMB on preformed bioﬁlms
In order to test the AMB ability to destroy preformed bioﬁlms,
C. tropicalis bioﬁlms were formed during 24 h at 37 °C and 120 rpm, in
RPMI medium. For that, 200 μL of each Candida suspension, containing
1 × 105 cells/mL in RPMI medium supplemented with 2% of glucose,
was added to the respective 96-well microplates. After the bioﬁlm for-
mation, the entire medium was aspirated, and different concentrations
of AMB (0.5, 1, 2, and 10 mg/L) prepared in RPMI medium were added
to the speciﬁc wells. The microplates were incubated for additional 48
h at 37 °C and 120 rpm. Controls were also performed with Candida
cells without antifungal agents. The experiments were repeated in trip-
licate on 3 different occasions.
2.4. Bioﬁlm analyses
2.4.1. Bioﬁlm total biomass
Bioﬁlm total biomass was quantiﬁed by crystal violet (CV) stain-
ing (Silva et al., 2009). For that, the medium was totally aspirated,
and the nonadherent cells were removed by washing the bioﬁlms
once with 200 μL of PBS. The bioﬁlm was ﬁxed with 200 μL of meth-
anol (100% v/v), which was removed after 15 min of contact. The mi-
croplates were allowed to dry at room temperature, and 200 μL of CV
(1% v/v) was added to each well and incubated for additional 5 min.
The wells were then gently washed twice with 200 μL of sterile ultra-
pure water, and 200 μL of acetic acid (33% v/v) was added to release
and dissolve the absorbed stain. The absorbance of the obtained so-
lution was read in triplicate in a microplate reader at 570 nm. The re-
sults were presented as absorbance per unit of area (Abs570nm/cm2).
2.4.2. Bioﬁlm cultivable cells
The number of cultivable cells in bioﬁlms was determined by the
enumeration of CFUs. For that, the medium was aspirated, and thebioﬁlms were washed once with 200 μL of PBS to remove nonadherent
cells. Then, the bioﬁlm was scraped from the 96-well microplates, and
the suspensions were vigorously vortexed for 2 min to disaggregate
cells from the matrix. In addition, in order to conﬁrm the complete re-
moval of the bioﬁlms from the wells, after bioﬁlm scraping, a CV stain-
ing was performed. Serial 10-fold dilutions in PBS were plated in SDA
and incubated at 37 °C for 24 h. The results were presented as the
total of CFUs per unit of area (log10 CFUs/cm2).
2.4.3. Bioﬁlm structure
The structure of preformed bioﬁlmswas examined by scanning elec-
tron microscopy (SEM). For the conditions tested (absence or presence
of 2 mg/L of AMB), bioﬁlms were formed into 24-well microplates
(Orange Scientiﬁc, Braine-l’ Alleud, Belgium) with an inoculum of
1mL of yeast cell suspension containing 1 × 105 cells/mL in RPMImedi-
um, as described previously.
The samples were dehydrated with increasing percentages of etha-
nol (using 70% ethanol for 10 min, 95% ethanol for 10 min, and 100%
ethanol for 20 min) and air dried for additional 20 min. Samples were
kept in a desiccator until the base of thewells wasmounted onto alumi-
num stubs, sputter coated with gold, and observed with an S-360 SEM.
2.5. Bioﬁlm matrix composition analysis
2.5.1. Matrix extraction method
Bioﬁlms for analysis of matrix compounds were formed in 24-well
microplates, in order to obtain a higher amount of biomass. As such, an
inoculum of 1 mL of yeast cell suspension (1 × 105 cells/mL in RPMI me-
dium) was added to each well, and bioﬁlms were formed as described
previously for preformed bioﬁlms. After 24 h, themediumwas aspirated,
and 2 mg/L of AMB was added to the speciﬁc wells and incubated for
more 48 h at 37 °C and 120 rpm. Controls were also performed with
Candida cells growing in the absence of AMB. After 48 h, the bioﬁlms
were washed once with 1mL of ultrapure water to remove nonadherent
cells, and the bioﬁlms were scraped from the wells and resuspended in
500 μL of ultrapure water. The suspensions were vortexed for 2 min
andﬁltered through a 0.20-μmﬁlter to evaluate the dryweight of the bio-
ﬁlm. The remaining suspension was sonicated for 30 s at 30W, vortexed
for 2min, and centrifuged at 5000g for 10min at 4 °C, in order to recover
only the matrix, which was stored at−20 °C before analysis. The exper-
iments were performed in triplicate and in 3 independent assays.
2.5.2. Proteins and carbohydrates quantiﬁcation
The proteins' content of the bioﬁlmmatrix of C. tropicalis strainswas
measured using the bicinchoninic acid kit (Thermo Fisher Scientiﬁc,
Rockford, IL, USA), using bovine serum albumin as standard. The absor-
bance was determined in a microplate reader at 562 nm.
The total carbohydrate content of the bioﬁlm matrix of C. tropicalis
strains was estimated according to the procedure of DuBois et al.
(1956), using glucose as standard. The absorbance was read in a
96-well microplate reader at 490 nm.
2.6. Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 software
forWindows. The results were compared using a 2-way analysis of var-
iance with the Bonferroni post hoc test. All tests were performed with a
95% conﬁdence level.
Fig. 1. Effect of AMB on C. tropicalis bioﬁlm formation after 48 h. (A)Mean values of the logarithmof CFUs normalized by unit of area (log10 CFU/cm2). (B)Mean values of the absorbance at
570 nm normalized by unit of area (Abs570nm/cm2). Error bars indicate the SD. *, **, and **** correspond to P b 0.05, P b 0.01, and P b 0.0001, respectively.
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3.1. Effect of the AMB on C. tropicalis planktonic cells
The results revealed that all C. tropicalis strains were resistant to
AMB according to the MIC breakpoint of CLSI (N2 mg/L) (Table 1). The
C. tropicalis strain that showed the lowest value of MIC (2.5–4 mg/L)
was the clinical isolate from the urinary tract, C. tropicalis 519468.
3.2. Amphotericin B effect on C. tropicalis bioﬁlms
3.2.1. Inﬂuence of AMB on bioﬁlm formation
The results revealed signiﬁcant reductions in the number of viable
cells of the 3 strains (Fig. 1A) and in total biomass values (Fig. 1B) in
the presence of the higher concentrations of AMB (1 and 2 mg/L), com-
pared to the control condition (P b 0.0001). Moreover, it was also veri-
ﬁed that there is a signiﬁcant reduction on bioﬁlm formation (in terms
of total biomass and number of cultivable cells) in the presence of the
lowest concentration of AMB (0.5 mg/L), for the 3 C. tropicalis strains
studied (Fig. 1A and B, respectively), compared to bioﬁlms formed in
the absence of the AMB (P b 0.05 or P b 0.01), except in the case of the
total biomass for C. tropicalis 519468 (Fig. 1B).
3.2.2. Amphotericin B effect against preformed bioﬁlms
In can be observed that the effect of AMB against C. tropicalis
preformed bioﬁlms (Fig. 2) is not so notorious as the effect on bioﬁlm
formation (Fig. 1). In fact, only the highest concentration of AMB testedFig. 2. Effect of AMB against 24 h preformed C. tropicalis bioﬁlms during additional 48 h. (A) M
values of the absorbance at 570 nm normalized by unit of area (Abs570nm/cm2). Error bars ind
respectively.(10 mg/L) was capable of causing a signiﬁcant reduction in the number
of viable cells (Fig. 2A) but only for C. tropicalis 12 (P b 0.01) and
C. tropicalis 519468 (P b 0.05) bioﬁlms. It is important to address that
the treatment of preformed bioﬁlms with AMB resulted in an increase
of the total biomass values (Fig. 2B), speciﬁcally for the lowest concen-
trations of AMB (0.5, 1, and 2 mg/L) in the case of C. tropicalis AG1, 12,
and 519468, compared to the control (P b 0.01 only for 0.5 and 1 mg/L
of AMB, P b 0.0001 and P b 0.001, respectively).
3.3. Effect of AMB on C. tropicalis bioﬁlm structure and matrix composition
SEM analysiswas performed to examine the effect of the AMB on the
structure of C. tropicalis preformed bioﬁlms. As such, each bioﬁlm was
treatedwith AMB (2mg/L) (Fig. 3, II) and comparedwith the respective
untreated bioﬁlm (Fig. 3, I). It was evident that C. tropicalis bioﬁlms are
formed by different yeast morphologies in a strain-dependent manner
(Fig. 3, I). C. tropicalisAG1 bioﬁlm is constituted by higher quantity ofﬁl-
amentous forms (Fig. 3A, I) presenting a more continuous layer, while
C. tropicalis 12 (Fig. 3B, I) and C. tropicalis 519468 (Fig. 3C, I) presented
bioﬁlms with lower quantity of ﬁlamentous forms.
Interestingly, itwas observed that C. tropicalisbioﬁlms,when treated
with AMB (Fig. 3, II), presented a more compact and continuous struc-
ture with the cells more interlinked. In fact, after treatment of the
bioﬁlms with AMB, they appear with more compact aspect and with
all cells embedded into the extracellular matrix (ECM) (Fig. 3, I). More-
over, in the presence of AMB, C. tropicalis bioﬁlms presented a reduction
in the number of ﬁlamentous forms (Fig. 3, II).ean values of the logarithm of CFUs normalized by unit of area (log10 CFU/cm2). (B) Mean
icate the SD. *, **, ***, and **** correspond to P b 0.05, P b 0.01, P b 0.001, and P b 0.0001,
Fig. 3. Scanning electronmicroscopy images of 24 h preformed C. tropicalis bioﬁlms. AG1 (A), C. tropicalis 12 (B), and C. tropicalis 519468 (C) bioﬁlms grown inRPMImedium for additional
48 h (I) in the absence of amphotericin B and (II) in the presence of 2 mg/L of the AMB. The bar in the images corresponds to 20 μm. Magniﬁcation ×1000.
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trix production and composition, the total protein and carbohydrate
content were also determined (Table 2).
Concerning the total protein content, the results showed a signiﬁ-
cant increase in the bioﬁlm matrices treated with 2 mg/L of AMB for
the 3 C. tropicalis strains tested (P b 0.0001 for C. tropicalis AG1 and
C. tropicalis 12 and P b 0.001 for C. tropicalis 519468). It should be
noted that the C. tropicalis 519468 bioﬁlm's matrices presented approx-
imately half of the protein composition, compared to C. tropicalis AG1
and C. tropicalis 12, in the absence and presence of AMB.
Regarding the results obtained with respect to the analysis of the
carbohydrate content, an increase after bioﬁlm treatment with 2 mg/L
of AMB, in the case of the C. tropicalis AG1 and C. tropicalis 519468,
was also observed, in comparison to the absence of AMB (P b 0.01). In
contrast, C. tropicalis 12 bioﬁlmmatrices showed a signiﬁcant reduction
in the carbohydrates values (P b 0.001). Moreover, likewise to protein
content, C. tropicalis 519468 showed the lower carbohydrate content
in the absence and presence of AMB, in comparison to the other 2
C. tropicalis strains tested.4. Discussion
C. tropicalis has been reported to be 1 of the Candida species that is
most likely to cause bloodstream and urinary tract infections in hospi-
talized patients and alsowith high potential for dissemination,mobility,
and mortality (Kothavade et al., 2010; Negri et al., 2010, 2012; SilvaTable 2
Effect of the AMB in the C. tropicalis preformed bioﬁlm matrix composition in terms of









AG1 0 17.519 ± 1.963 285.365 ± 0.273
2 22.383 ± 0.607⁎⁎⁎⁎ 333.963 ± 0.287⁎⁎
12 0 14.568 ± 1.220 363.476 ± 1.184
2 23.220 ± 0.845⁎⁎⁎⁎ 294.998 ± 31.520⁎⁎⁎
519468 0 6.304 ± 0.085 133.174 ± 21.349
2 10.212 ± 1.009⁎⁎⁎ 190.519 ± 0.262⁎⁎
Mean ± SD values of the proteins (mg protein/g dry weight bioﬁlm) and carbohydrates
(mg carbohydrate/g dry weight bioﬁlm).
⁎⁎ P b 0.01, when the presence of AMB was compared to its absence.
⁎⁎⁎ P b 0.001, when the presence of AMB was compared to its absence.
⁎⁎⁎⁎ P b 0.0001, when the presence of AMB was compared to its absence.et al., 2011, 2012). This is due to several virulence factors exhibited by
C. tropicalis, namely, the bioﬁlm formation ability, since the bioﬁlms
confer signiﬁcant resistance to antifungal therapy and host immune re-
sponses (Negri et al., 2012; Silva et al., 2009, 2011, 2012;Williams et al.,
2011). Additionally, it is known that C. tropicalis isolates have the ability
to form compact bioﬁlms. Thus, the main aim of this study was to infer
about the AMB ability to control and combat C. tropicalis bioﬁlms and to
determine the role of the matrix compounds in the C. tropicalis bioﬁlm
resistance to AMB.
In the clinical perspective, the most important characteristic of
Candida species is their ability to form bioﬁlms and their role in the in-
creased tolerance to conventional antifungal therapy, since they are
much more resistant to antifungal agents than planktonic cells
(Donlan and Costerton, 2002; Fonseca et al., 2014; Galán-Ladero et al.,
2013; Shanmughapriya et al., 2014; Silva et al., 2012). As expected, all
strains were able to form bioﬁlms and exhibited resistance to AMB but
in a strain-dependent manner (Table 1). Additionally, the strain with
lower MIC value is also the strain that presented the lowest ability to
form bioﬁlm. These results appear to be in agreement with previous
studies involving C. tropicalis bioﬁlms (Galán-Ladero et al., 2013;
Shanmughapriya et al., 2014).
Moreover, in general, C. tropicalis bioﬁlms aremore resistant toAMB,
when the bioﬁlms were formed before the addition of this antifungal
agent. In fact, some studies reported that C. tropicalis planktonic cells
were susceptible to AMB, although their bioﬁlms exhibited resistance,
normally due to the synthesis of large amounts of matrix (Al-Fattani
and Douglas, 2006; Bizerra et al., 2008; Kothavade et al., 2010; Negri
et al., 2012; Silva et al., 2009). This fact was also described by other au-
thors for Candida albicans and Candida glabrata bioﬁlms (Fonseca et al.,
2014; Kumamoto, 2002; Silva et al., 2012). As it is well known, mature
bioﬁlms are in cells organized into structured communities embedded
within an ECM (Negri et al., 2012; Silva et al., 2009, 2011, 2012). The
matrix production has been reported as a Candida response to stress
conditions, namely, to the presence of antifungal agents (Al-fattani
and Douglas, 2004; Silva et al., 2011, 2012). From the analysis of the re-
sults obtained (Fig. 2B), it is possible to assume that bioﬁlmmatrix may
have a role in the bioﬁlm resistance to this agent. Notwithstanding the
inherent destructive nature of the preparation of samples to be ob-
served in the SEM,with the possible loss of some cells andmatrix during
the dehydration process of this technique, it is possible to observe that
C. tropicalis bioﬁlms consist of a dense network of cells with a variety
of cell morphologies (Fig. 3, I), presenting a mixture of yeast cells and
evidentﬁlamentousmorphologies, in agreementwithwhatwas already
169T. Fernandes et al. / Diagnostic Microbiology and Infectious Disease 83 (2015) 165–169described (Donlan and Costerton, 2002; Silva et al., 2009, 2011). These
results are in accordance with the values of total biomass obtained
(Fig. 2B) and also highlight the important role of the bioﬁlm matrix in
the Candida resistance to AMB.
Generally, the bioﬁlm matrix compounds include (in addition to
water): carbohydrates, proteins, hexosamines, and phosphorus (Baillie
and Douglas, 2000; Silva et al., 2009, 2012). Our results point out to
the fact that AMB, besides inducing changes in the structure of
C. tropicalis bioﬁlms (Fig. 3), can also cause alterations in their matrix
composition (Table 2). It can be speculated that AMBmight then trigger
the protein and carbohydrate production, resulting in a well-structured
and dense bioﬁlm. Thus, it is possible to assume that the matrix in-
crease, in particular of protein and carbohydrate contents, may contrib-
ute to the C. tropicalis bioﬁlm resistance to AMB.
5. Conclusions
In conclusion, this work demonstrated that AMB is unable to totally
prevent bioﬁlm formation and to eradicate C. tropicalis preformed
bioﬁlms. The signiﬁcant increase of the protein and carbohydrate con-
tents in the bioﬁlms matrices treated with AMB seems to be the main
explanation to the increase of C. tropicalis bioﬁlm resistance. More
in vitro (medical devices) and in vivo models can be used in the future
to corroborate these results.
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